Twist Bioscience Corporation balance sheet TWST

Annual Quarterly

As of Jun 30, 2026, Twist Bioscience Corporation had total assets of $672.4 million and total liabilities of $226.7 million. Total assets were up 4.5% from a year earlier. Stockholders' equity was $445.7 million. It held $166.8 million in cash and investments against $93.6 million of total debt, net cash of $73.2 million. The current ratio, current assets divided by current liabilities, was 2.67.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Sep 30, 2025
FY 2024
Sep 30, 2024
FY 2023
Sep 30, 2023
FY 2022
Sep 30, 2022
FY 2021
Sep 30, 2021
FY 2020
Sep 30, 2020
FY 2019
Sep 30, 2019
Assets
Cash
117
-41.7%
183
-19.1%
226
-21.0%
286
-24.4%
379
-18.7%
466
+397.3%
94
+100.4%
47
Short-term investments
49
-0.0%
49
-1.4%
50
+0.3%
50
-60.5%
126
+949.4%
12
-93.9%
196
+114.9%
91
Cash and investments
167
-33.5%
232
-15.9%
276
-17.8%
336
-33.4%
505
+5.7%
478
+64.8%
290
+110.0%
138
Receivables
65
+30.5%
57
+63.4%
35
-20.8%
44
+9.4%
40
+41.1%
29
+8.2%
26
+117.9%
12
Inventory
35
+35.6%
28
+17.6%
24
-24.9%
32
-18.4%
39
+23.6%
32
+158.8%
12
+67.7%
7
Total current assets
321
-5.4%
333
-4.0%
347
-18.3%
424
-28.9%
596
+9.1%
546
+63.2%
335
+109.1%
160
Property and equipment, net
112
+17.3%
102
-0.2%
103
-22.2%
132
-5.5%
139
+216.0%
44
+73.3%
25
+22.2%
21
Goodwill
82
+0.0%
82
-4.2%
86
+0.0%
86
+0.0%
86
+282.5%
22
+1871.4%
1
+0.0%
1
Total assets
672
+4.5%
642
+4.5%
614
-20.9%
776
-19.2%
961
+36.9%
702
+76.0%
399
+113.3%
187
Liabilities and equity
Accounts payable
17
+42.2%
11
+580.6%
2
-88.4%
14
-30.1%
20
+34.8%
15
+208.5%
5
-50.5%
10
Total current liabilities
120
+38.1%
91
+28.7%
71
-3.2%
73
-19.1%
91
+43.8%
63
+75.0%
36
+18.7%
30
Total liabilities
227
+37.1%
169
+19.3%
142
-7.4%
153
-11.1%
172
+41.8%
121
+93.7%
63
+79.4%
35
Stockholders' equity
446
-6.8%
473
+0.1%
473
-24.2%
623
-21.0%
789
+35.9%
581
+72.7%
336
+121.1%
152
Debt
Debt due within a year
—
—
—
—
0
-100.0%
2
-62.7%
3
+0.0%
3
Long-term debt
—
—
—
—
—
—
1
-68.1%
4
Lease liabilities
94
+19.8%
76
-11.1%
85
-9.6%
94
-0.9%
95
+54.7%
61
+96.4%
31
—
Total debt
94
+19.8%
76
-11.1%
85
-9.6%
94
-0.9%
95
+47.6%
63
+77.7%
36
+365.3%
8
Net cash
73
-57.6%
157
-18.0%
191
-21.0%
242
-40.9%
410
-0.8%
415
+63.0%
254
+94.8%
130
Ratios
Current ratio
2.67x
3.64x
4.88x
5.79x
6.58x
8.67x
9.29x
5.28x
Debt to equity
0.21x
0.16x
0.18x
0.15x
0.12x
0.11x
0.11x
0.05x
Return on equity
-30.67%
-16.42%
-44.16%
-32.82%
-27.60%
-26.19%
-41.61%
-70.80%
Return on assets
-20.33%
-12.10%
-33.98%
-26.35%
-22.66%
-21.66%
-35.08%
-57.58%
Book value per share
7.11
7.80
8.03
10.83
13.97
11.73
7.46
4.63
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
TWST (Nasdaq)
Fiscal year ends
September 30
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
Large accelerated filer
SEC CIK
1581280

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.